Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
Autore:
McDermott, DF; Mier, JW; Lawrence, DP; van den Brink, MRM; Clancy, MA; Rubin, KM; Atkins, MB;
Indirizzi:
Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol & Oncol,Dept Med, Boston, MA 02215 USA Harvard Univ Boston MA USA 02215 l & Oncol,Dept Med, Boston, MA 02215 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 6, volume: 6, anno: 2000,
pagine: 2201 - 2208
SICI:
1078-0432(200006)6:6<2201:APIPTO>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED TRIAL; COMBINATION; THERAPY; CHEMOTHERAPY; TAMOXIFEN; ALFA-2A; CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Atkins, MB Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Dept Med, East Campus,Kirstein 158, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr East Campus,Kirstein 158 Boston MA USA 02215
Citazione:
D.F. McDermott et al., "A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma", CLIN CANC R, 6(6), 2000, pp. 2201-2208

Abstract

In an effort to develop a biochemotherapy regimen for metastatic melanoma suitable for testing in a cooperative group setting, we modified the concurrent biochemotherapy regimen of S. S. Legha et al. (J. Clin. Oncol., 16: 1752-1759, 1998) by providing enhanced supportive care and developing a strict, conservative approach to the management of treatment-related toxicities,Patients received cisplatin, vinblastine, and dacarbazine (CVD: cisplatin (20 mg/m(2)) and vinblastine (1.2 mg/m(2)) on days 1-4, dacarbazine (800 mg/ m(2)) on day 1 only) concurrently with interleukin 2 (9 MIU/ m(2)/day) bycontinuous i.v. infusion on days 1-4 and IFN-alpha (5 MU/m(2)/day) on days1-5, 8, 10, and 12, Prophylactic antibiotics and a maximum of four cycles were administered. Routine granulocyte colony-stimulating factor and aggressive antiemetics were initiated after patients 7 and 14, respectively. Forty-four patients were enrolled in this study. No patients had received priorchemotherapy or interleukin 2; however, 23 (53%) had received prior IFN-alpha, mostly in the adjuvant setting, A total of 131 treatment cycles was administered. Significant toxicities requiring dose modification included: hypotension requiring pressors (15 episodes in 11 patients), grades 3/4 vomiting (12 episodes in 15 cycles; 5 episodes in 12 patients (6 episodes in 9 cycles after initiation of the modified antiemetic regimen), transient renalinsufficiency (5 episodes in 5 patients), grade 4 thrombocytopenia (24 episodes, 1 associated with bleeding), neutropenia with or without fever (15 instances, only 11 in 112 cycles after routine use of granulocyte colony-stimulating factor), and catheter-related bacteremia (2 patients). Five (16%) of 30 patients who were treated after the last protocol modification experienced what we defined as unacceptable toxicity for a cooperative group setting. Responses were seen in 19 of 40 evaluable patients (relative risk, 48%) with 8 complete responses (20%). The median response duration was 7 months (range, 1-17+ months) with one currently ongoing. The central nervous system was the initial site of relapse in 11 responding patients. The median survival duration was 11 months (range, 2 31 months). This modified, concurrent biochemotherapy regimen is active and tolerable for use in a cooperative group setting. Central nervous system relapse, however, remains a concernfor responders. This regimen is being compared with CVD in a Phase III Intergroup Trial (Eastern Cooperative Oncology Group/Southwest Oncology Group 3695).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 21:59:13